Every year, two million people worldwide die due to chronic liver disease, with 1 million of those fatalities coming from cirrhosis-related complications, and 1 million from hepatic cancer and viral hepatitis. Hepatocellular carcinoma is currently the 16th most prevalent cause of mortality worldwide, while cirrhosis is currently the 11th; together, they account for 3.5% of all mortality worldwide. The complex process of liver regeneration or treatment restores functional tissues after injury/resection and hepatic parenchymal cells undergo momentary ATP depletion and undergo metabolic stress. When cells are under stress, heat shock protein acts as a chaperone and triggers the release of various inflammatory cytokines which have been recognized as important participants in the initial phases of liver regeneration. Heat shock proteins were thought to be an emerging therapeutic target for chronic hepatic disease due to their participation in the development of a number of liver ailments. In this study, we concentrate on how various liver-related disorders are treated by natural, synthetic, and semi-synthetic medications that regulate heat shock proteins